TISSUE DONATION IS CRITICAL TO FIND TREATMENTS! Click here to learn more.
Advisory Board
Denise Adams, MD
Dr. Adams is pediatric hematologist-oncologist and Director of the Complex Vascular Anomalies Program (CVAP) at Children's Hospital of Philadelphia (CHOP). Prior to this role, Dr. Adams was Co-Director of Vascular Anomalies Center at Boston Children's Hospital. Before moving to Boston, she was a pediatric hematologist oncologist at Cincinnati Children's Hospital Medical Center. She received her medical degree from Georgetown University School of Medicine and has been in practice for more than 20 years.
Dr Adams has extensive experience with EHE in both children and adults. She was one of the first physicians who started using mTor inhibitors for EHE treatment. Dr. Adams is loved by her patients for her warm heart and unlimited dedication.
Scott Okuno, MD
Dr. Okuno is a Professor of Oncology at the Mayo Clinic in Rochester, Minnesota. His focus is on clinical trials for patients with sarcomas as well as patients with head and neck cancers. His research encourages a multidisciplinary approach with surgeons and radiation oncologists.
Dr. Okuno’s professional highlights include working as a medical officer, serving with the Sarcoma Alliance for Research Through Collaboration, founding the Midwest Sarcoma Trials Partnership, and working alongside the Sarcoma Working Group and Radiation Therapy Oncology Group.
Vinod Ravi, MD
Dr. Ravi is an Assistant Professor in the Department of Sarcoma Medical Oncology at M.D. Anderson Cancer Center in Houston, Texas. His clinical practice is focused on vascular sarcomas.
He has conducted several Phase II and III studies in patients with various sarcomas. Dr. Ravi is interested in correlating responses to specific targeted therapies with molecular predictors to improve clinical trial efficiency and success rates.
Dr. Ravi sees a vast majority of EHE patients in the United States.
Brian Rubin, MD, PhD
Dr. Rubin is Chair of the Robert J. Tomsich Pathology & Laboratory Medicine Institute (RT-PLMI) at the Cleveland Clinic. He is a world-renowned pathologist and medical researcher who has made invaluable contributions to sarcoma diagnosis and treatment.
Dr. Rubin is a global leader in EHE research. He is also a deeply respected friend to the EHE community: patients know him as not only a great scientist but also as a truly approachable and caring individual who is always willing to consider cases and give critical advice.
Silvia Stacchiotti, MD
Dr. Stacchiotti is a medical oncologist at the Istituto Nazionale Tumori in Milan, Italy. She has one of the most active EHE practices in the world.
At the American Society of Clinical Oncoloy (ASCO) in 2013, Dr. Stacchiotti presented her research titled, “Sirolimus in advanced hemangioendothelioma,” which was the first encouraging study showing a response in EHE patients to mTor inhibitors.
She presented more data at the Connective Tissue Oncology Society in 2015 that showed even more promise and raised interest among sarcoma specialists.
Dr. Stacchiotti consults EHE patients from around the world.
William Tap, MD
Dr. Tap is a chief of Sarcoma Services at Memorial Sloan Kettering Hospital in New York. He received his medical degree from Jefferson Medical College. Dr. Tap has a large clinical practice and develops and runs clinical trials that evaluate the use of new anticancer treatments. Dr. Tap has a strong focus on laboratory research that strives to better understand the genetic origins of sarcoma.
Cameron Trenor III, MD
Dr. Trenor is a Co-Director of Cerebrovascular Disorders and Stroke Program
at Boston Children's Hospital. He is also a Director of Clinical Research at the Vascular Anomalies Center. He is particularly interested in developing novel therapies for patients with vascular malformations and tumors.
Dr. Trenor had his pediatric hematology oncology fellowship training at Boston Children's Hospital and Dana-Farber Cancer Institute. He treats both children and adults with EHE in the Boston area, as well as consults with patients in the US and abroad.
Jonathan C. Trent, MD, PhD
Dr. Trent is the Director of the Bone and Soft-tissue Sarcoma Group and an Associate Director for Clinical Research, Sylvester Comprehensive Cancer Center in Miami, Florida.
Prior to joining the Sylvester Comprehensive Cancer Center, Trent was an associate professor of medicine in sarcoma medical oncology at the M. D. Anderson Cancer Center in Houston, Texas.
Dr. Trent’s interests are in the clinical and translational research of sarcomas, direct care of sarcoma patients, and sarcoma education. As Associate Director for Clinical Research, his goal is to develop clinical trials that provide molecular testing of a patient’s tumor and molecularly targeted therapy to cancer patients.
Breelyn Wilky, MD
Dr. Wilky is Associate Professor, Division of Medical Oncology, Director of Sarcoma Translational Research at the University of Colorado Anschutz Medical Campus, School of Medicine.
She is a translational researcher who conducts and designs clinical trials for sarcoma patients. Dr. Wilky also works with laboratory researchers to translate the latest findings from bench research into early phase clinical trials. She is an expert not only in traditional chemotherapy treatments for sarcomas, but also at using modern technology such as gene sequencing and molecular profiling to identify out-of-the-box treatments particularly in targeted therapy.
She is also interested in novel immunotherapy approaches and is currently conducting a study that is open to EHE patients that combines immunotherapy and anti-angiogenic drugs.